APLS Apellis Pharmaceuticals, Inc.: institutional ownership and insider trading
20 funds reported holding $327M of Apellis Pharmaceuticals, Inc. in their latest 13F filings; in Q2 2026 funds net sold $5.80B, with 0 new positions and 321 funds selling out; over the last 12 months insiders bought $0 and sold $2.79M on the open market.
Largest institutional holders of APLS
- VANGUARD GROUP INC — $268M
- Nuveen Asset Management, LLC — $15.7M
- Camber Capital Management LP — $14.7M
- JANUS HENDERSON GROUP PLC (JHG) — $10.1M
- Cubist Systematic Strategies, LLC — $6.78M
- EFG Asset Management (North America) Corp. — $3.52M
- WOLVERINE TRADING, LLC — $3.00M
- CIBRA Capital Ltd — $2.01M
- Point72 Hong Kong Ltd — $859K
- HAP TRADING, LLC — $571K
Recent APLS insider trades
- Feb 11, 2026: DeLong Mark Jeffrey sold 368 shares ($8.15K)
- Jan 22, 2026: Watson David O. sold 7,832 shares ($171K)
- Jan 22, 2026: Sullivan Timothy Eugene sold 10,287 shares ($224K)
- Jan 22, 2026: Nicholson Nur sold 7,725 shares ($168K)
5%+ owners
- STATE STREET CORPORATION: 5.4% (Schedule 13G, filed May 12, 2026)